熱門資訊> 正文
Adial Pharmaceuticals宣布360万美元的公开募股定价
2025-06-17 20:52
- Adial Pharmaceuticals (NASDAQ:ADIL) on Tuesday announced the pricing of its public offering for the purchase and sale of 11.1M shares of common stock of the company, together with Series D warrants to purchase up to 11.1M shares of common stock and Series E warrants to purchase up to 8.33M shares of common stock at a combined offering price of $0.3251 per share and accompanying warrants, for aggregate gross proceeds of about $3.6M.
- The Series D warrants and the Series E warrants will have an exercise price of $0.35 per share.
- The closing of the offering is expected to occur on or about June 18, 2025.
- In connection with the offering, the company also agreed to amend certain existing Series B-1 warrants to purchase up to 2.48M shares of common stock and certain existing Series C-1 warrants to purchase up to 4.03M shares of common stock with an exercise price of $0.74 per share.
- ADIL -30.29% premarket to $0.2266.
- Source: Press Release
More on Adial Pharmaceuticals
- Seeking Alpha’s Quant Rating on Adial Pharmaceuticals
- Financial information for Adial Pharmaceuticals
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。